about
Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitorsTranslocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myelomaCoexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsAPOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaThe Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaImmunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.Treatment of Newly Diagnosed Elderly Multiple Myeloma.Prognostic value of PINI index in patients with multiple myeloma.Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study.Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.Understanding the multiple biological aspects leading to myelomaPixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.Early coagulopathy in trauma patients: an on-scene and hospital admission study.Novel M-component based biomarkers in Waldenström's macroglobulinemiaOngoing development of monoclonal antibodies and antibody drug-conjugates in lymphomaAbsence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphomaEvaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case SeriesIbrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case seriesDaratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life populationManagement and outcome of primary CNS lymphoma in the modern era: An LOC network studyDaratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trialBRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaThe genomic landscape of plasma cells in systemic light chain amyloidosis
P50
Q24305602-5E0ACD74-340B-40A7-8F36-D60D1F9E6EA7Q34410261-9F00EB6A-C0B0-4C66-B535-9F685C78821CQ34435295-CBA2503D-C03C-4C09-9BF0-97004454CF74Q35025456-20534DA1-808A-40C9-961A-94DBAE1B172CQ35081172-A2617C83-D2EF-4D62-9E91-88D35790415DQ36055752-CCEE2283-9D8D-42EB-9AC8-04EA3267C9EFQ37443338-FA53BD4B-DB1D-4F7E-BFBE-C62375E45AD1Q37528072-A5E54145-F36A-4B01-BD38-39D8E4405A64Q38065298-FA6A9558-9FF6-4D2A-8B8A-D108F10EEB3AQ38087742-51121529-4854-49D4-9DEA-EF49A9161621Q38373226-B00D2846-D18E-4DF4-8CB3-675A47A721FEQ38742055-9ABEDE77-D24F-4B34-BCB6-BE5A12627C3AQ38760679-EE1D47A8-667D-4714-A82E-A65CB0FDB4B8Q38815405-212784D5-6CEB-4205-BEDB-5745CE93B4FFQ39681433-D74AF644-9ED1-4207-A4EF-F8C40B4E511BQ40300472-AACFC00A-EA88-4E9B-A00F-646D678EF8DBQ40303771-70C7E798-BDFD-47EA-A907-8E2FC90645F0Q40633414-1F744E57-9B93-4217-9F3D-D41F943A92C3Q40678259-BA667697-2949-4267-9E52-DDE91FAAB3A5Q41195432-F601EFC5-917D-45E6-83FB-052F8214CDF6Q42385107-23ACC31B-A63A-478E-83DC-221A5E0980D9Q43412243-A92FDC85-1166-412F-ADE7-5BA619EB2C6DQ44818652-0F26AB4E-1D0D-4951-A15F-E9D5DA8D716AQ46912713-2B511214-BDED-4E18-9CA9-FA3A4D7E2177Q83757892-B2A577E3-5764-489A-A137-F0045C412EB1Q84774081-C1214560-E1B3-4155-A901-463B1CCEF47AQ86643391-AC734C24-D9EE-4FB7-8D50-10CD0BC47616Q88030952-AC6DF705-50B1-48A5-A358-03A436046C31Q88799540-3B6284D0-0F73-4113-94DC-44E434F054EEQ91336407-FCFB113F-B67F-4649-B352-76AEEF85CB63Q92452920-4B0DF280-DC4E-4172-899E-0EA1F093CD26Q92892510-26C021A8-4F10-459E-BE69-E1305D2F4D1EQ92977400-D5EF3817-6597-4262-9022-EE7BAD902A4DQ93182963-105738F5-5E62-4B4F-B83B-F3B594071A0C
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Eileen M Boyle
@ast
Eileen M Boyle
@en
Eileen M Boyle
@en-gb
Eileen M Boyle
@es
Eileen M Boyle
@nl
Eileen M Boyle
@sl
type
label
Eileen M Boyle
@ast
Eileen M Boyle
@en
Eileen M Boyle
@en-gb
Eileen M Boyle
@es
Eileen M Boyle
@nl
Eileen M Boyle
@sl
prefLabel
Eileen M Boyle
@ast
Eileen M Boyle
@en
Eileen M Boyle
@en-gb
Eileen M Boyle
@es
Eileen M Boyle
@nl
Eileen M Boyle
@sl
P106
P31
P496
0000-0001-8791-1744